BioCryst Pharmaceuticals
Commercializes oral ORLADEYO and develops injectable navenibart for hereditary angioedema.
Something off on this page? Send us feedback.
Profile
Commercializes ORLADEYO for hereditary angioedema and RAPIVAB for influenza, while developing navenibart and BCX17725 for rare diseases. Revenue is concentrated in ORLADEYO, with direct U.S. commercialization and partner-led overseas markets.
Commercializes ORLADEYO, a once-daily oral plasma kallikrein inhibitor that prevents hereditary angioedema attacks, and RAPIVAB, an intravenous influenza treatment. ORLADEYO generates nearly all product revenue and is sold directly in the United States, with overseas markets served through licensing and distribution partners.
Develops navenibart, a long-acting injectable plasma kallikrein inhibitor in late-stage testing for hereditary angioedema, and BCX17725, an early-stage KLK5 inhibitor for Netherton syndrome. The Astria Therapeutics acquisition added navenibart and expanded the franchise beyond oral small molecules.
Uses a rare-disease commercial platform while shifting pipeline sourcing toward external innovation after deciding to close its internal discovery operation. Revenue remains concentrated in ORLADEYO, and investigational programs depend on clinical results and regulatory approvals.
Company facts
Key statistics
Year to date +30.9% · Average volume (30d) 3.0M
Analysts
Ratings
Target range
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 7, 2026 | RBC Capital | Reiterate | Outperform | $15 | $14 |
| Jun 30, 2026 | Cantor Fitzgerald | Reiterate | Overweight | $21 | $29 |
| Jun 30, 2026 | Jefferies | Reiterate | Buy | $15 | $17 |
| Nov 5, 2025 | JMP Securities | Target | $25 | ||
| Nov 4, 2025 | Barclays | Reiterate | Equal Weight | $7 | $9 |
Earnings
EPS
Revenue
History
| Report date | EPS est | EPS | Surprise | Revenue est | Revenue | Surprise | Next session |
|---|---|---|---|---|---|---|---|
| Aug 5, 2026Q2 FY26 | $0.15 | $0.30 | +94.6% | $183.3M | $218.3M | +19.1% | +0.55% |
| May 6, 2026Q1 FY26 | $0.06 | −$0.03 | −150.0% | $151.1M | $156.4M | +3.5% | +0.79% |
| Feb 26, 2026Q4 FY25 | $0.07 | $1.12 | +1,500.0% | $151.3M | $406.6M | +168.7% | +10.76% |
| Nov 3, 2025Q3 FY25 | $0.07 | $0.06 | −14.3% | $151.3M | $159.4M | +5.3% | −1.46% |
Financial highlights
| 12 quarters | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | |
|---|---|---|---|---|---|---|---|
| Revenue | $145.5M | $163.4M | $159.4M | $406.6M | $156.4M | $218.3M | |
| Gross profit | $141.0M | $160.6M | $156.9M | $396.6M | −$546.7M | $214.4M | |
| Operating income | $21.2M | $29.8M | $29.6M | $260.4M | −$701.6M | $98.5M | |
| Net income | $32.0K | $5.1M | $12.9M | $245.8M | −$721.8M | $78.4M | |
| Diluted EPS | $0.00 | $0.02 | $0.06 | $1.12 | −$2.98 | $0.30 | |
| Gross margin | 96.9% | 98.3% | 98.4% | 97.6% | -349.5% | 98.2% | |
| Operating margin | 14.6% | 18.2% | 18.6% | 64.0% | -448.6% | 45.1% |
Fiscal years (4-quarter sums)FY21 $157.2M · FY22 $270.8M · FY23 $331.4M · FY24 $450.7M · FY25 $874.8M
Revenue by product · Q2 FY26
Balance sheet, Jun 30, 2026Cash & short-term investments $352.6M · Total debt $409.9M · Total assets $557.9M · Shareholders' equity −$454.3M
Dividends
No dividends on record.
Ownership
A 13F quarter can total more than the shares outstanding — sub-advisers file the same block twice, and a filer's own share count can be a quarter stale. No split is drawn from it.
Shares outstanding 254.16M · Float 214.93M · 84.6% free float
Top shareholders13F · 13D/G · Form 4
| Holder | Shares | % outstanding | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 23.89M | 9.40% | 13F | Aug 7, 2026 |
| Ra Capital Management, L.P. | 15.83M | 6.23% | 13F | Aug 14, 2026 |
| State Street Corp | 15.19M | 5.98% | 13F | Aug 7, 2026 |
| Deerfield Management Company, L.P. (Series C) | 15.10M | 5.94% | 13F | Aug 14, 2026 |
| Deerfield Mgmt, L.P. | 14.34M | 6.81% | 13G | Feb 12, 2026 |
Insider tradesForm 4
| Date | Insider | Role | Shares | Avg price |
|---|---|---|---|---|
| May 18, 2026 | Amy E. McKee | director | −11,180 | $8.97 |
| May 13, 2026 | Alane P. Barnes | officer: Chief Legal Officer | −62,500 | $9.54 |
| Mar 20, 2026 | Theresa Heggie | director | −49,933 | $10.11 |
| Mar 16, 2026 | Alane P. Barnes | officer: Chief Legal Officer | −150,000 | $9.15 |
| Dec 22, 2025 | Alane P. Barnes | officer: Chief Legal Officer | −21,773 | $7.65 |
Peers
- Takeda (ADR)
Broadest HAE franchise; TAKHZYRO ~$1.7B/yr is the #1 SC prophylactic globally
- Ionis Pharmaceuticals
DAWNZERA (donidalorsen), FDA-approved SC RNA-targeted HAE prophylaxis Q4W/Q8W
- Intellia Therapeutics
One-time CRISPR KLKB1 edit for HAE; HAELO Phase 3 positive, BLA rolling 2026
- Pharvaris
Oral B2 antagonist deucrictibant in Phase 3 for HAE on-demand and prophylaxis
CompareAfter-hours close
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| BioCryst Pharmaceuticals | $9.82 | 0.00% | $2.50B | — | 18.7 | 2.7 | +33.6% |
| Takeda (ADR) | $18.49 | +2.53% | $57.37B | 51.0 | 53.7 | 2.0 | +5.8% |
| Ionis Pharmaceuticals | $61.05 | +0.02% | $10.15B | — | — | 11.6 | −40.7% |
| Intellia Therapeutics | $12.87 | −0.01% | $1.80B | — | — | 30.2 | −46.2% |
| Pharvaris | $35.40 | +0.14% | $2.47B | — | — | — | — |
| Median | 51.0 | 53.7 | 11.6 | −40.7% |